Skip to main content
John Welch, MD, Oncology, Saint Louis, MO

JohnSuttonWelchMD

Oncology Saint Louis, MO

Associate Professor, Internal Medicine, Division of Oncology, Washington University in St. Louis School of Medicine

Dr. Welch is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Welch's full profile

Already have an account?

Education & Training

  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2006 - 2010
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2004 - 2006
  • University of California San Diego School of Medicine
    University of California San Diego School of MedicineClass of 2004

Certifications & Licensure

  • MO State Medical License
    MO State Medical License 2007 - 2025
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Elected Member ASCI, 2017

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • TP53 Immunohistochemistry Correlates TP53 Mutation Status and Clearance in Decitabine-Treated Patients with Myeloid Malignancies  
    John S Welch, Eric J Duncavage, Haematologica
  • Exome Analysis of Treatment‐Related AML After APL Suggests Secondary Evolution  
    John S Welch, Eric J Duncavage, Meagan A Jacoby, Peter Westervelt, Lukas D Wartman, British Journal of Haematology

Abstracts/Posters

  • Whole Genome Bisulfite Sequencing of 63 Primary AML Samples Identifies a Unique DNA Hypermethylation Signature for Mutant IDH1/2 Cases That Is Different from That of T...
    John S. Welch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
    John S. Welch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Endogenous Retinoid X Receptor Ligands Act As Tumor Suppressors in MLL-AF9 Mouse Leukemia
    John S. Welch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • The Ugly: p53-Mutated Acute Myeloid Leukemia—Can It Be Solved? 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • Notable Launches New Clinical Study with Washington University School of Medicine Exploring Ex Vivo Drug Screening to Predict Chemotherapy Sensitivity and Resistance
    Notable Launches New Clinical Study with Washington University School of Medicine Exploring Ex Vivo Drug Screening to Predict Chemotherapy Sensitivity and ResistanceAugust 6th, 2020
  • $11.5 Million Supports Innovation in Leukemia Research
    $11.5 Million Supports Innovation in Leukemia ResearchNovember 6th, 2018
  • Decitabine in TP53-Mutated AML
    Decitabine in TP53-Mutated AMLFebruary 23rd, 2017
  • Join now to see all

Other Languages

  • German